Industry Outlook 2025: The Future of Technology in the Biopharma Industry

Technologies such as artificial intelligence (AI) and machine learning (ML) are advancing quickly in many industries, including the biopharmaceutical industry. One challenge in the implementation of these technologies in biopharma, according to Edwin Stone, CEO of Cellular Origins, is the data sets and the sensitivity surrounding it.

“There's a huge amount of proprietary data,” Stone says. “And so, I think [this is] something actually, as an industry, we're really going to have to think about a lot harder than we had previously. And remembering here, we're in an industry where, by solving these problems, we help make people better. How do we collaborate better? How do we understand and separate out the competitive landscape from our ability to make enormous strides for us? And I think [it] will be a massive shame for the industry if we all operate in our silos and we miss out on the benefit that I think a lot of those data processing technologies could have. I think the other piece, of course, with this is AI and ML are having a huge impact on [drug] discovery, and I think in the world, in the virtual world, in the software world, that's unsurprisingly, where they found their home.”

Click the video above to watch the full interview.

About the speaker

Edwin Stone is CEO of Cellular Origins.